Last Price
0.264
Today's Change
-0.011 (4.00%)
Day's Change
0.245 - 0.276
Trading Volume
1,099,861
Exchange: NASDAQ Capital Market NASDAQ Capital Market
Currency: USD USD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Thomas A. Fitzgerald M.B.A. Mr. Thomas A. Fitzgerald M.B.A.
Full Time Employees: 10 10
IPO Date: 2021-07-08 2021-07-08
CIK: 0001829635 0001829635
ISIN: US89357L3033 US89357L3033
CUSIP: 89357L105 89357L105
Beta: 0.47 0.47
Last Dividend: 0.00 0.00
Dcf Diff: -3.85 -3.85
Dcf: 7.66 7.66
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.